After a high-throughput screening, we found that dihydroartemisinin treatment significantly reduced c-Myc protein levels in SW480, and the late-stage CRC such as SW620, DLD-1, and HCT116 in a dose-dependent manner (Fig. 2A). This evidence concerns the gene MYC and colorectal carcinoma.